Neoplasms of the adrenal cortex Clinical and basic aspects

  • Ana C. Latronico
  • George P. Chrousos
Chapter
Part of the Cancer Treatment and Research book series (CTAR, volume 89)

Abstract

Cushing’s syndrome due to adrenocortical tumors was reported at the turn of the century, almost a decade before the description of the syndrome and homonymous disease by Harvey Cushing [1]. At the time, the adrenal cortices were known to secrete an active principle necessary for life, the absence of which led to Addison’s disease. However, the crucial role of the pituitary gland in the control of adrenal secretion was not suspected. Since then, we have learned a great deal about adrenocortical tumors, their incidence, clinical presentation, diagnosis, therapy, and prognosis. Some research on the cell biology of these tumors has also been done, mostly in the last decade. Rapidly advancing knowledge in the biology of other more frequent nonendocrine or endocrine tumors promises that better understanding of adrenal tumorigenesis is also forthcoming.

Keywords

Congenital Adrenal Hyperplasia Adrenal Mass Adrenocortical Carcinoma Adrenocortical Tumor Adrenal Cortical Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Medvei VC. 1982. A History of Endocrinology. Hingham, MA: MTP Press.CrossRefGoogle Scholar
  2. 2.
    Ross NS, Aron DC. 1990. Hormonal evaluation of the patient with an incidentally discovered adrenal mass. N Engl J Med 323:1401–1405.PubMedCrossRefGoogle Scholar
  3. 3.
    Abecassis M, McLoughlin MJ, Langer B, Kudlow JE. 1985. Serendipitous adrenal masses: Prevalence, significance, and management. Am J Surg 149:783–788.PubMedCrossRefGoogle Scholar
  4. 4.
    Bertagna C, Orth David. 1981. Clinical and laboratory findings and results of therapy in 58 patients with adrenocortical tumors admitted to a single medical center (1951 to 1978). Am J Med 71:855–875.PubMedCrossRefGoogle Scholar
  5. 5.
    Sullivan M, Boileau M, Hodges CV. 1978. Adrenal cortical carcinoma. J Urol 120:660–665.PubMedGoogle Scholar
  6. 6.
    Nader S, Hickey RC, Sellin RV, Samaan NA. 1983. Adrenal cortical carcinoma. A study of 77 cases. Cancer 52:707–711.PubMedCrossRefGoogle Scholar
  7. 7.
    Flack MR, Chrousos GP. 1996. Neoplasms of adrenal cortex. In JF Holland, RC Bast Jr, DL Morton, E Frei III, DW Kufe, RR Weichselbaum, Eds. Cancer Medicine, 4th edi., Williams and Wilkins, Baltimore Vol 1, pp 1563–1570.Google Scholar
  8. 8.
    Stewart DR, Jones PHM, Jolleys A. 1974. Carcinoma of the adrenal gland in children. J Pediatr Surg 9:59–67.PubMedCrossRefGoogle Scholar
  9. 9.
    Henley DJ, van Heerden JA, Grant CS, Carney A, Carpenter PC. 1983. Adrenal cortical carcinoma — A continuing challenge. Surgery 94:926–931.PubMedGoogle Scholar
  10. 10.
    Chudler RM, Kay R. 1989. Adrenocortical carcinoma in children. Urol Clin North Am 163:469–479.Google Scholar
  11. 11.
    Mendonca BB, Lucon AM, Menezes CAV, Saldanha LB, Latronico AC, Zerbini C, Madureira G, Domenice S, Albergaria MA, Camargo MH, Halpern A, Liberman B, Arnhold IJP, Bloise W, Andriolo A, Nicolau W, Silva FAQ, Wroclaski E, Arap S, Wajchenberg BL. 1995. Clinical, hormonal and pathological findings in a comparative study of adrenal cortical neoplasms in childhood and adulthood. J Urol, 154:2004–2009.PubMedCrossRefGoogle Scholar
  12. 12.
    Luton JP, Cerdas S, Billaud L, Thomas G, Guilhaume B, Bertagna X, Laudat MH, Louvel A, Chapius Y, Blondeau P, Bonnin A, Bricaire H. 1990. Clinical features of adrenocortical carcinoma, prognostic factors and the effect of mitotane therapy. N Engl J Med 322:1195–1201.PubMedCrossRefGoogle Scholar
  13. 13.
    Barzilay JI, Pazianos AG. 1989. Adrenocortical carcinoma. Urol Clin North Am 16:457–468.PubMedGoogle Scholar
  14. 14.
    Pang S, Becker D, Cotelingham J, et al. 1981. Adrenocortical tumor in a patient with congenital adrenal hyperplasia due to 21-hydroxylase-deficiency. Pediatrics 68:242–246.PubMedGoogle Scholar
  15. 15.
    Bauman A, Bauman CG. 1982. Virilizing adrenocortical carcinoma: Development in a patient with salt-losing congenital adrenal hyperplasia. JAMA 248:3140–3141.PubMedCrossRefGoogle Scholar
  16. 16.
    Carney JA, Young WF. 1992. Primary pigmented nodular adrenocortical disease and its associated conditions. Endocrinologist 2:6–21.CrossRefGoogle Scholar
  17. 17.
    Third National Cancer Survey: Incidence Data National Cancer Institute Monograph 41. March 1975. DHEW Publication No. (NIH) 75–787; US Department of Health. Education and Welfare: Public Health Service, Bethesda, MD: National Institute of Health, National Cancer Institute.Google Scholar
  18. 18.
    Young JL Jr, Miller RW. 1975. Incidence of malignant tumors in U.S. children. J Pediatr 86:254–258.PubMedCrossRefGoogle Scholar
  19. 19.
    King DR, Lack EE. 1979. Adrenal cortical carcinoma. A clinical and pathologic study of 49 cases. Cancer 44:239–244.PubMedCrossRefGoogle Scholar
  20. 20.
    Pommier RF, Brennan MF. 1992. An eleven-year experience with adrenocortical carcinoma. Surgery 112:963–971.PubMedGoogle Scholar
  21. 21.
    Crapo L. 1979. Cushing’s syndrome a review of diagnostic test. Metabolism 28:955–977.PubMedCrossRefGoogle Scholar
  22. 22.
    Shapiro B, Fig LM, Gross MD, Khafagi F. 1990. Contributions of nuclear endocrinology to the diagnosis of adrenal tumors. Recent Results Cancer Res 118:113–138.PubMedCrossRefGoogle Scholar
  23. 23.
    Jones GS, Shan KJ, Mann JR. 1985. Adreno-cortical carcinoma in infancy and childhood: A radiological report of ten cases. Clin Radiol 36:257–262.PubMedCrossRefGoogle Scholar
  24. 24.
    Daneman A, Chan HSL, Martin J. 1983. Adrenal carcinoma and adenoma in children: A review of 17 patients. Pediatr Radiol 13:11–18.PubMedCrossRefGoogle Scholar
  25. 25.
    Eghraki M, McLoughlin MJ, Rose IE, St. Louis EL, Wilson SR, Yeung HP. 1980. The role of computed tomography in assessment of tumoral pathology of the adrenal glands. J Comput Assist Tomogr 4:71–77.CrossRefGoogle Scholar
  26. 26.
    Glazer GM, Woolsey EJ, Borello J, et al. 1986. Adrenal tissue characterization using MRI imaging. Radiology 158:73–79.PubMedGoogle Scholar
  27. 27.
    Ribeiro RC, Sandrini Neto RS, Schell MJ, Lacerda L, Sampaio GA. 1990. Adrenocortical carcinoma in children: A study of 40 cases. J Clin Oncol 8:67–74.PubMedGoogle Scholar
  28. 28.
    Hogan TF, Gilchrist KW, Westring DW, Citrin DL. 1980. A clinical and pathological study of adrenocortical carcinoma: Therapeutics implications. Cancer 45:2880–2883.PubMedCrossRefGoogle Scholar
  29. 29.
    Weiss LM. 1984. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am J Surg Pathol 8:163–169.PubMedCrossRefGoogle Scholar
  30. 30.
    Saeger. 1990. Tumours of the adrenal gland. Recent Results Cancer Res 118:79–96.PubMedCrossRefGoogle Scholar
  31. 31.
    Bowlby LS, DeBault L, Abraham SR. 1986. Flow cytometric analysis of adrenal cortical tumor DNA. Cancer 58:1499–1505.PubMedCrossRefGoogle Scholar
  32. 32.
    Taylor S, Roederer M, Murphy R. 1987. Flow cytometric DNA analysis of adrenocortical tumors in children. Cancer 59:2059–2063.PubMedCrossRefGoogle Scholar
  33. 33.
    Macfarlane DA. 1958. Cancer of the adrenal cortex: The natural history, prognosis and treatment in a study of fifty-five cases. Ann Coll Surg Eng 23:155–186.Google Scholar
  34. 34.
    Brennam MF. 1987. Adrenocortical carcinoma. Cancer 37:348–365.Google Scholar
  35. 35.
    Schwarz RJ, Schimidt N. 1991. Efficient management of adrenal tumors. Am J Surg 161:576–579.PubMedCrossRefGoogle Scholar
  36. 36.
    Hutter AM, Kayhoe DE. 1966. Adrenal cortical carcinoma: Results of treatment with o′p′ DDD in 138 patients. Am J Med 41:581.PubMedCrossRefGoogle Scholar
  37. 37.
    Schteingart DE. 1992. Treating adrenal cancer. Endocrinologist 2:149–157.CrossRefGoogle Scholar
  38. 38.
    Flack MR, Pyle RG, Mullen NM, Lorenzo B, Wu YW, Knazek. Nisula BC, Reidenberg MM. 1993. Oral gossypol in the treatment of metastatic adrenal cancer. J Clin Endocrinol Metab 76:1019–1024.PubMedCrossRefGoogle Scholar
  39. 39.
    Haq MM, Legha SS, Samaan NA, Bodey GP, Burgess MA. 1980. Cytotoxic chemotherapy in adrenal cortical carcinoma. Cancer Treat Rep 64:909–913.PubMedGoogle Scholar
  40. 40.
    Hesketh PJ, McCaffrey RP, Finkel HE, Larmon SS, Griffing GT, Melby JC. 1987. Cisplatin-based treatment of adrenocortical carcinoma. Cancer Treat Rep 71:222–224.PubMedGoogle Scholar
  41. 41.
    Johnson DH, Greco FA. 1986. Treatment of metastatic adrenal cortical carcinoma with cisplatin and etoposide (VP-16). Cancer 58:2198–2202.PubMedCrossRefGoogle Scholar
  42. 42.
    Schlumberger M, Ostronoff M, Bellaiche M, Rougier P, Droz JP, Parmentier C. 1988. 5-Fluorouracil, doxorubicin, and cisplatin regimen in adrenal cortical carcinoma. Cancer 61:1492–1494.PubMedCrossRefGoogle Scholar
  43. 43.
    van Slooten H, van Oosterom AT. 1983. CAP (cyclophosphamide, doxorubicin, and cisplatin) regimen in adrenal cortical. Cancer Treat Rep 67:377–379.PubMedGoogle Scholar
  44. 44.
    Boveri TH. 1914. Zur Frage der Enstsehung maligner Tumoren. Jena: Verlag von Gustav Fisher.Google Scholar
  45. 45.
    Duffy MJ. 1993. Cellular oncogenes and suppressor genes as prognostic markers in cancer. Clin Biochem 26:439–447.PubMedCrossRefGoogle Scholar
  46. 46.
    Weinberg RA. 1992. The integration of molecular genetics into cancer management. Cancer 70:1653–1658.PubMedCrossRefGoogle Scholar
  47. 47.
    Sugimura T, Terada M, Yokota J, Hirohashi S, Wakabayashi K. 1992. Multiple genetic alterations in human carcinogenesis. Environ Health Perspect 98:5–12.PubMedCrossRefGoogle Scholar
  48. 48.
    Beuschlein F, Reincke M, Karl M, Travis WD, Jaursch-Hancke C, Abdelhamid S, Chronsos GP, Allolio B. 1994. Clonal composition of human adrenocortical neoplasms. Cancer Res 54:4927–4932.PubMedGoogle Scholar
  49. 49.
    Gicquel C, Leblond-Francillard M, Bertagna X, Louvel A, Chapuis Y, Luton JP, Girard F, LeBouc Y. 1994. Clonal analysis of human adrenocortical carcinomas and secreting adenomas. Clin Endocrinol (Oxf) 40:465–477.CrossRefGoogle Scholar
  50. 50.
    Weiner T, Cance WG. 1994. Molecular mechanisms involved in tumorigenesis and their surgical implications. Am J Surg 167:428–434.PubMedCrossRefGoogle Scholar
  51. 51.
    Hartwell LH, Kastan MB. 1994. Cell cycle control cancer. Science 266:1821–1828.PubMedCrossRefGoogle Scholar
  52. 52.
    Webster K, Cavenee, White RL. 1995. The genetic basis of cancer. Sci Am March: 74–79.Google Scholar
  53. 53.
    Allen LF, Lefkowitz RJ, Caron MG, Cotecchia S. 1991. G-protein-coupled receptors as protooncogenes: Constitutively activating mutations of the α1B-adrenergic receptor enhances mitogenesis and tumorigenesis. Proc Natl Acad Sci USA 88:11354–11358.PubMedCrossRefGoogle Scholar
  54. 54.
    Parma J, Duprez L, Van Sande J, Cochaux P, Gervy C, Mockel J, Dumont J, Vassart G. 1993. Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature 365:649–651.PubMedCrossRefGoogle Scholar
  55. 55.
    Mountjoy KG, Robbins LS, Marty TM, Cone RD. 1992. The cloning of a family of genes that encode the melanocortin receptors. Science 257:1248–1251.PubMedCrossRefGoogle Scholar
  56. 56.
    Vamvakopoulos NC, Rojas K, Overhauser, Durkin S, Nierman WC, Chrousos GP. 1993. Mapping the human melanocortin 2 receptor (adrenocorticotropic hormone receptor; ACTHR) gene (MCR2) to the small arm of chromosome 18 (18p11.21-pter). Genomics 18:454–455.PubMedCrossRefGoogle Scholar
  57. 57.
    Latronico AC, Reincke M, Mendonça BB, Arai K, Mora P, Allolio B, Wajchenberg BI, Chrousos GP, Tsigos C. 1995. No evidence for oncogenic mutations in the adrenocorticotropin receptor (ACTH-R) gene in human adrenocortical neoplasms. J Clin Endocrinol Metab 80:875–877.PubMedCrossRefGoogle Scholar
  58. 58.
    Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel A. 1991. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 325:1688–1695.PubMedCrossRefGoogle Scholar
  59. 59.
    Lyons J, Landid CA, Harsh G, Vallar L, Grunewald K, Feichtinger H, Duh QY, Clark OH, Kawasaki E, Bourne HR. 1990. Two G protein oncogenes in human endocrine tumors. Science 249:655–659.PubMedCrossRefGoogle Scholar
  60. 60.
    Reincke M, Karl M, Travis W, Chrousos GP. 1993. No evidence for oncogenic mutations in guanine nucleotide-binding proteins of human adrenocortical neoplasms. J Clin Endocrinol Metabol 77:1419–1422.CrossRefGoogle Scholar
  61. 61.
    Nishizuka Y. 1984. The role of protein kinase C in cell surface signal transduction and tumour promotion. Nature 308:693–698.PubMedCrossRefGoogle Scholar
  62. 62.
    Castagna M, Takai Y, Kaibuichi K, Sano K, Kikkawa U, Nishizuka Y. 1982. Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters. J Biol Chem 257:7847–7851.PubMedGoogle Scholar
  63. 63.
    O’Brian CA, Vogel VG, Singletary SE, Ward NE. 1989. Elevated protein kinase C expression in human breast tumor biopsies relative to normal breast tissue. Cancer Re 49:3215–3217.Google Scholar
  64. 64.
    Alvaro V, Touraine P, Raisman Vozari R, Bai-Grenier F, Birman P, Joubert (Bression) D. 1992. Protein kinase C activity and expression in normal and adenomatous human pituitaries. Int J Cancer 50:724–730.PubMedCrossRefGoogle Scholar
  65. 65.
    Coudwell WT, Antel JP, Yong VW. 1992. Protein kinase C activity correlates with the growth rate of malignant gliomas: Part II. Effects of glioma mitogens and modulators of protein Kinase C. Neurosurgery 31:717–724.CrossRefGoogle Scholar
  66. 66.
    Latronico AC, Mendonça BB, Bianco AC, Villares SM, Lucon MA, Nicolau W, Wajchenberg BL. 1994. Calcium-dependent protein kinase-C activity in human adrenocortical neoplasms, hyperplastic adrenals, and normal adrenocortical tissue. J Clin Endocrinol Metab 79:736–739.PubMedCrossRefGoogle Scholar
  67. 67.
    Li FP, Fraumeni JF. 1982. Prospective study of a family cancer syndrome. JAMA 247:2692–2694.PubMedCrossRefGoogle Scholar
  68. 68.
    Malkin D, Li FP, Strong LC, Fraumeni JF, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA, Friend SH. 1990. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233–1238.PubMedCrossRefGoogle Scholar
  69. 69.
    Warneford SG, Wilton LJ, Townsend ML, Rowe PB, Reddel RR, Dalla-Pozza L, Symonds G. 1992. Germ-line splicing mutation of the p53 gene in a cancer-prone family. Cell Growth Differ 3:839–846.PubMedGoogle Scholar
  70. 70.
    Levine AJ, Momand J, Finlay CA. 1991. The p53 tumour suppressor gene. Nature 351:453–456.PubMedCrossRefGoogle Scholar
  71. 71.
    Hollstein M, Sidransky D, Vogestein B, Harris CC. 1991. P53 mutations in human cancer. Science 253:49–53.PubMedCrossRefGoogle Scholar
  72. 72.
    Roemer K, Friedmann T. 1994. Mechanisms of action of the p53 tumor suppressor and prospects for cancer gene therapy by reconstitution of p53 function. Ann NY Acad Sci 716:265–282.PubMedCrossRefGoogle Scholar
  73. 73.
    Fromentel CC, Soussi T. 1992. tp53 tumor suppressor gene: A model for investigating human mutagenesis. Genes Chromosom Cancer 4:1–15.CrossRefGoogle Scholar
  74. 74.
    Lin SR, Lee YJ, Tsai JH. 1994. Mutations of the p53 gene in human functional adrenal neoplasms. J Clin Endocrinol Metab 78:483–491.PubMedCrossRefGoogle Scholar
  75. 75.
    Reincke M, Karl M, Travis WH, Mastorakos G, Allolio B, Linehan HM, Chrousos GP. 1994. p53 mutations in human adrenocortical neoplasms: Immunohistochemical and molecular studies. J Clin Endocrinol Metab 78:790–794.PubMedCrossRefGoogle Scholar
  76. 76.
    Horowitz JM, Park S-H, Bogenmann E, Cheng J-C, Yandell DW, Kaye FJ, Minna JD, Dryja TP, Weinberg RA. 1990. Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. Proc Natl Acad Sci USA 87:2775–2779.PubMedCrossRefGoogle Scholar
  77. 77.
    Warneford S, Townsend M, Rowe PB, Dalla-Pozza L, Symonds G. 1991. Overexpression of the retinoblstoma gene in a familial adrenocortical carcinoma. Cell Growth Differ 2:439–445.PubMedGoogle Scholar
  78. 78.
    Marx J. 1994. New tumor suppressor may rival p53. Science 264:344–345.PubMedCrossRefGoogle Scholar
  79. 79.
    Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS 3rd, Johnson BE, Skolnick MH. 1994. A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436–440.PubMedCrossRefGoogle Scholar
  80. 80.
    Marx J. 1994. A challenge to pl6 gene as a major tumor suppressor. Science 264:1846.PubMedCrossRefGoogle Scholar
  81. 81.
    Lange T. 1994. Activation of telomerase in a human tumor. Proc Natl Acad Sci USA 91:2882–2885.PubMedCrossRefGoogle Scholar
  82. 82.
    Counter CM, Hirte HW, Bacchetti S, Harley CB. 1994. Telomerase activity in human ovarian carcinoma. Proc Natl Acad Sci USA 91:2900–2904.PubMedCrossRefGoogle Scholar
  83. 83.
    Kerr JFR, Winterford CM, Harmon BV. 1994. Apoptosis. Its significance in cancer and cancer therapy. Cancer 73:2013–2026.PubMedCrossRefGoogle Scholar
  84. 84.
    Ruoslahti E, Reed J. 1994. Anchorage dependence, integrins, and apoptosis. Cell 77:477–478.PubMedCrossRefGoogle Scholar
  85. 85.
    Fisher DE. 1994. Apoptosis in cancer therapy: Crossing the threshold. Cell 78:539–542.PubMedCrossRefGoogle Scholar
  86. 86.
    Fishel R, Lescoe MK, Rao MR, Copeland NG, Jenkins NA, Garber J, Kane M, Kolocher R. 1993. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 75:1027–1038.PubMedCrossRefGoogle Scholar
  87. 87.
    Papadopoulos V, Berkovich A, Krueger KE. 1991. The role of diazepam binding inhibitor and its processing products at mitochondrial benzodiazepine receptors: Regulation of steroid biosynthesis. Neuropharmacology 30:1417–1423.PubMedCrossRefGoogle Scholar
  88. 88.
    Papadopoulos V. 1993. Peripheral-type benzodiazepine/diazepan binding inhibitor receptor: Biological role in steroidogenic cell function. Endocr Rev 14:222–240.PubMedGoogle Scholar
  89. 89.
    Lin D, Sugawara T, Strauss JF 3rd, Clark BJ, Stocco DM, Saenger P, Rogol A, Miller WL. 1995. Role of steroidogenic acute regulatory protein in adrenal and gonadal steroidogenesis. Science 267:1780–1781.CrossRefGoogle Scholar
  90. 90.
    Parker KL, Schimmer BP. 1993. Transcriptional regulation of adrenal steroidogenic enzymes. Trends Endocrinol Metab 4:46–50.PubMedCrossRefGoogle Scholar
  91. 91.
    Ikeda Y, Shen W-H, Ingraham HA, Parker K. 1994. Developmental expression of mouse steroidogenic factor-1, an essential regulator of steroid hydroxylase. Mol Endocrinol 8:654–662.PubMedCrossRefGoogle Scholar
  92. 92.
    Luo X, Ikeda Y, Parker K. 1994. A cell-specific nuclear receptor is essential for adrenal and gonadal development and sexual differentiation. Cell 77:481–490.PubMedCrossRefGoogle Scholar
  93. 93.
    Muscatelli F, Strom TM, Walker AP, Zanaria E, Recan D, Meindl A, Bardoni B, Guioli S, Zehetner G, Rabl W, Schwarz HP, Kaplan J-C, Camerino G, Meitinger T, Monaco AP. 1994. Mutations in the DAX-1 gene give rise to both X-linked hypoplasia congenita and hypogonadotropic hypogonadism. Nature 372:672–676.PubMedCrossRefGoogle Scholar
  94. 94.
    Zanaria E, Muscatelli F, Bardoni B, Strom TM, Guioli S, Guo W, Lalli E, Moser C, Walker AP, McCabe ERB, Meitinger T, Monaco AP, Sassone-Corsi P, Camerino G. 1994. An unusual member of the nuclear hormone receptor superfamily responsible for X-linked adrenal hypoplasia congenita. Nature 372:635–641.PubMedCrossRefGoogle Scholar
  95. 95.
    Thiebaut F, Tsuruo T, Hamada, Gotlesman MM, Pastan I, Willingham MC. 1987. Cellular localization of the multidrug-resistance gene product P-glycoprtotein in normal human tissues. Proc Natl Acad Sci USA 84:7735–7738.PubMedCrossRefGoogle Scholar
  96. 96.
    Miller RW. 1978. Peculiarities in the occurrence of adrenal cortical carcinoma. Am J Dis Child 132:235.PubMedGoogle Scholar
  97. 97.
    Levine GW. 1978. Adrenocortical carcinoma in two children with subsequent primary tumors. Am J Dis Child 132:238–240.PubMedGoogle Scholar
  98. 98.
    Didolkar MS, Bescher A, Elias G, Moore RH. 1981. Natural history of adrenal cortical carcinoma: A clinicopathologic study of 42 patients. Cancer 47:2153–2161.PubMedCrossRefGoogle Scholar
  99. 99.
    Junien C. 1992. Beckwith-Wiedmann syndrome, tumourigenesis and imprinting. Curr Opin Genet Dev 2:431–438.PubMedCrossRefGoogle Scholar
  100. 100.
    Ping AP, Reeve AE, Law DJ, Young MR, Boehnke M, Feinberg AP. 1989. Genetic linkage of Beckwith-Wiedmann syndrome to 11p15. Am J Hum Genet 44:720–723.PubMedGoogle Scholar
  101. 101.
    Koufos A, Hansen MF, Copeland NG, Jenkins NA, Lampkin BC, Cavenee WK. 1987. Loss of heterozygosity in three embryonal tumours suggests a common pathogenic mechanism. Nature 316:330–334.CrossRefGoogle Scholar
  102. 102.
    Gicquel C, Xavier B, Schneid H, Francillard-LeBlond M, Luton JP, Girard F, LeBouc Y. 1994. Rearrangement at the Ilpl5 locus and overexpression of insulin-like growth factor-II gene in sporadic adrenocortical tumors. J Clin Endocrinol Metab 78:1444–1453.PubMedCrossRefGoogle Scholar
  103. 103.
    Yano T, Linehan M, Anglard P, Lerman MI, Daniel LN, Stein CA, Robertson CN, LaRocca R, Zbar B. 1989. Genetic changes in human adrenocortical carcinoma. J Natl Cancer Inst 81:518–523.PubMedCrossRefGoogle Scholar
  104. 104.
    Rosenberg C, Delia-Rosa VA, Latronico AC, Mendonca BB, Vianna-Morgante AM. 1995. Selection of adrenal tumor cells in culture demonstrated by interphase cytogenetics. Cancer Genet Cytogenet 79:36–40.PubMedCrossRefGoogle Scholar
  105. 105.
    Carney JA, Gordon H, Carpenter PC, Shenoy BV, Go VLW. 1985. The complex of myxomas, spotty pigmentation, and endocrine overactivity. Medicine (Baltimore) 64:270–283.Google Scholar
  106. 106.
    Young WF Jr, Carney JA, Musa BU, Wulffraat NM, Lens JW, Drexhage HA. 1989. Familial Cushing’s syndrome due to primary pigmented nodular adrenocortical disease. Reinvestigation 50 years later. N Engl J Med 321:1659–1664.PubMedCrossRefGoogle Scholar
  107. 107.
    Stratakis CA, Carney A, Ping J, Papanicolaou DA, Karl M, Kastner DL, Pras E, Chrousos GP. 1996. Carney Complex, a Familial Multiple Neoplasia and Lentiginosis Syndrome: Analysis of 11 Kindreds and Linkage to the Short Arm of Chromosome 2. J. Clin Invest 97:699–705.CrossRefGoogle Scholar
  108. 108.
    Stratakis CA, Jenkins RB, Pras E, Mitsiadis CS, Raff SB, Stalboerger PG, Tsigos C, Carney A, Chrousos GP. 1996. Cytogenetic and Mircosatellite Alterations in Tumors from Patients with the Syndrome of Myxomas, Spotty Skin Pigmentation, and Endocrine Overactivity (Carney Complex). J Clin Endocrinol Metab 81:3607–3614.PubMedCrossRefGoogle Scholar
  109. 109.
    Wermer P. 1954. Genetics aspects of adenomatosis of endocrine glands. Am J Med 16:363–371.PubMedCrossRefGoogle Scholar
  110. 110.
    Larsson C, Friedman E. 1994. Localization and identification of the multiple endocrine neoplasia type 1 disease gene. Endocrinol Metabol Clin North Am 23:67–79.Google Scholar
  111. 111.
    Thakker RV. 1994. The role of molecular genetics in screening for multiple endocrine neoplasia type I. Endocrinol Metab Clin North Am 23:117–135.PubMedGoogle Scholar
  112. 112.
    Skogseid B, Larsson C, Lindgren PG, Kvanta E, Rastad J, Theodorsson E, Wide L, Wilander E, Oberg K. 1992. Clinical and genetic features of adrenocortical lesions in multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 75:76–81.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1997

Authors and Affiliations

  • Ana C. Latronico
  • George P. Chrousos

There are no affiliations available

Personalised recommendations